biostudies-literatureMaroni RNational Health ServiceCancer Research UKMedtronicYorkshire Cancer ResearchNIHR Cambridge Biomedical Research CentreMedical Research CouncilNational Institute for Health Research (NIHR)e054258https://www.ebi.ac.uk/biostudies/studies/S-EPMC8990713biostudies-literatureUnknown12(4)<h4>Objectives</h4>The BEST3 trial demonstrated the efficacy and safety of the Cytosponge-trefoil factor 3, a cell collection device coupled with the biomarker trefoil factor 3, as a tool for detecting Barrett's oesophagus, a precursor of oesophageal adenocarcinoma (OAC), in primary care. In this nested study, our aim was to understand patient experiences.<h4>Design</h4>Mixed-methods using questionnaires (including Inventory to Assess Patient Satisfaction, Spielberger State-Trait Anxiety Inventory-6 and two-item perceived risk) and interviews.<h4>Outcome measures</h4>Participant satisfaction, anxiety and perceived risk of developing OAC.<h4>Setting</h4>General practices in England.<h4>Participants</h4>Patients with acid reflux enrolled in the intervention arm of the BEST3 trial and attendiBMJ openPatient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial.PMC8990713C8162/A25356L389SSno award/grant numberRG84369C14478/A21047C7492/A17219C8162/A16892BRC-1215-20014Maroni ROffman JSasieni PWalter FMBarnes JScheibl FRubin GSmith SGBEST3 ConsortiumDebiram-Beecham IWaller JFitzgerald RCfalsePatient-reported experiences and views on the Cytosponge test: a mixed-methods analysis from the BEST3 trial.<h4>Objectives</h4>The BEST3 trial demonstrated the efficacy and safety of the Cytosponge-trefoil factor 3, a cell collection device coupled with the biomarker trefoil factor 3, as a tool for detecting Barrett's oesophagus, a precursor of oesophageal adenocarcinoma (OAC), in primary care. In this nested study, our aim was to understand patient experiences.<h4>Design</h4>Mixed-methods using questionnaires (including Inventory to Assess Patient Satisfaction, Spielberger State-Trait Anxiety Inventory-6 and two-item perceived risk) and interviews.<h4>Outcome measures</h4>Participant satisfaction, anxiety and perceived risk of developing OAC.<h4>Setting</h4>General practices in England.<h4>Participants</h4>Patients with acid reflux enrolled in the intervention arm of the BEST3 trial and attendi2022-01-01T00:00:00Z2022 Apr2025-04-05T22:15:38.794Z2025-04-05T22:15:38.794ZS-EPMC89907133539330810.1136/bmjopen-2021-054258